Pain Management & Interventional Pain
Interventional pain management clinics and chronic pain practices providing injection therapy and neuromodulation.
- 6
- Verticals
Overview
Pain Management & Interventional Pain covers interventional pain clinics and chronic-pain practices providing injection therapy, neuromodulation, and chronic-pain management. Demand is driven by chronic pain prevalence and the shift toward interventional and non-opioid pain treatment.
PE-backed pain platforms consolidate practices and ancillaries (ASCs, imaging, neuromodulation), though the specialty carries regulatory and reputational sensitivity around opioid prescribing. Interventional procedures and ASC migration drive the economics.
Market snapshot
Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so pain management is not separately sized.
Business model & economics
Revenue model
Procedure-driven interventional-pain reimbursement
Key economics
- Recurring revenue
- Moderate
- EBITDA margin
- 18–28% with ancillaries
- Capex intensity
- Moderate
chronic-pain management recurs
Characteristics
- Shift toward interventional, non-opioid pain treatment.
- ASC and neuromodulation ancillaries drive economics.
- Regulatory sensitivity around opioid prescribing.
M&A deal context
Who’s acquiring
- PE-backed pain platforms
- Specialty MSO consolidators
- ASC-aligned acquirers
What’s driving deals
- Roll-up for interventional and ASC economics.
- Chronic-pain and non-opioid-treatment demand.
- Regulatory scrutiny shaping the specialty.
Verticals in this segment
Find Pain Management & Interventional Pain acquisition targets
Search Acquisera’s index for companies classified under Pain Management & Interventional Pain (4.10.19) and build a targeted deal pipeline.
Search companies